Baudax Bioinc Stock Fundamentals
BXRX Stock | USD 0.02 0 5.88% |
Baudax BioInc fundamentals help investors to digest information that contributes to Baudax BioInc's financial success or failures. It also enables traders to predict the movement of Baudax Stock. The fundamental analysis module provides a way to measure Baudax BioInc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Baudax BioInc stock.
At this time, Baudax BioInc's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 25.4 M in 2024, whereas Operating Income is likely to drop (36.8 M) in 2024. Baudax | Select Account or Indicator |
Baudax Cash And Equivalents Analysis
Baudax BioInc's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
More About Cash And Equivalents | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 12.0M | 11.9M | 10.7M | 13.6M | Total Assets | 53.3M | 10.0M | 9.0M | 8.6M |
Cash | = | Bank Deposits | + | Liquidities |
Current Baudax BioInc Cash And Equivalents | 5.65 M |
Most of Baudax BioInc's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Baudax BioInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
In accordance with the recently published financial statements, Baudax BioInc has 5.65 M in Cash And Equivalents. This is 99.31% lower than that of the Biotechnology sector and 98.74% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.79% higher than that of the company.
Baudax BioInc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Baudax BioInc's current stock value. Our valuation model uses many indicators to compare Baudax BioInc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Baudax BioInc competition to find correlations between indicators driving Baudax BioInc's intrinsic value. More Info.Baudax BioInc is rated below average in shares owned by insiders category among related companies. It is rated below average in short ratio category among related companies fabricating about 19.00 of Short Ratio per Shares Owned By Insiders. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Baudax BioInc by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Baudax BioInc's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Baudax BioInc's earnings, one of the primary drivers of an investment's value.Baudax Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Baudax BioInc's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Baudax BioInc could also be used in its relative valuation, which is a method of valuing Baudax BioInc by comparing valuation metrics of similar companies.Baudax BioInc is currently under evaluation in price to earning category among related companies.
Baudax Fundamentals
Return On Equity | -47.04 | ||||
Return On Asset | -1.15 | ||||
Operating Margin | (27.60) % | ||||
Current Valuation | 17.72 M | ||||
Shares Outstanding | 43.59 M | ||||
Shares Owned By Insiders | 0.01 % | ||||
Shares Owned By Institutions | 2.68 % | ||||
Number Of Shares Shorted | 493.56 K | ||||
Price To Earning | 0.03 X | ||||
Price To Book | 0.68 X | ||||
Price To Sales | 0.75 X | ||||
Revenue | 1.27 M | ||||
Gross Profit | (5.74 M) | ||||
EBITDA | (34.76 M) | ||||
Net Income | (7.15 M) | ||||
Cash And Equivalents | 5.65 M | ||||
Cash Per Share | 0.28 X | ||||
Total Debt | 7.12 M | ||||
Debt To Equity | 2.26 % | ||||
Current Ratio | 0.53 X | ||||
Book Value Per Share | (0.84) X | ||||
Cash Flow From Operations | (14.31 M) | ||||
Short Ratio | 0.19 X | ||||
Earnings Per Share | (94.13) X | ||||
Target Price | 24.0 | ||||
Beta | 1.58 | ||||
Market Capitalization | 950.33 K | ||||
Total Asset | 10.03 M | ||||
Retained Earnings | (190.9 M) | ||||
Working Capital | (15.11 M) | ||||
Current Asset | 21.72 M | ||||
Current Liabilities | 7.92 M | ||||
Z Score | -39.68 | ||||
Net Asset | 10.03 M |
About Baudax BioInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Baudax BioInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Baudax BioInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Baudax BioInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Current Deferred Revenue | 6.4 M | 4.7 M | |
Total Revenue | 1.5 M | 1.5 M | |
Cost Of Revenue | 8.1 M | 4.1 M | |
Ebit Per Revenue | (40.29) | (42.31) |
Pair Trading with Baudax BioInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Baudax BioInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Baudax BioInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Baudax Stock
0.77 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Baudax Stock
0.74 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
0.72 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
0.71 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.63 | TCRX | Tscan Therapeutics Financial Report 8th of May 2024 | PairCorr |
0.59 | MGNX | MacroGenics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Baudax BioInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Baudax BioInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Baudax BioInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Baudax BioInc to buy it.
The correlation of Baudax BioInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Baudax BioInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Baudax BioInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Baudax BioInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Baudax BioInc Piotroski F Score and Baudax BioInc Altman Z Score analysis. For more information on how to buy Baudax Stock please use our How to Invest in Baudax BioInc guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Baudax Stock analysis
When running Baudax BioInc's price analysis, check to measure Baudax BioInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baudax BioInc is operating at the current time. Most of Baudax BioInc's value examination focuses on studying past and present price action to predict the probability of Baudax BioInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Baudax BioInc's price. Additionally, you may evaluate how the addition of Baudax BioInc to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Baudax BioInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Baudax BioInc. If investors know Baudax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Baudax BioInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (94.13) | Revenue Per Share 0.318 | Quarterly Revenue Growth (0.23) | Return On Assets (1.15) | Return On Equity (47.04) |
The market value of Baudax BioInc is measured differently than its book value, which is the value of Baudax that is recorded on the company's balance sheet. Investors also form their own opinion of Baudax BioInc's value that differs from its market value or its book value, called intrinsic value, which is Baudax BioInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Baudax BioInc's market value can be influenced by many factors that don't directly affect Baudax BioInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Baudax BioInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Baudax BioInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Baudax BioInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.